Phillips 66 to Host Annual Meeting of Shareholders
Get Alerts PSX Hot Sheet
Join SI Premium – FREE
HOUSTON--(BUSINESS WIRE)-- Phillips 66 (NYSE: PSX) will host its annual meeting of shareholders on Wednesday, May 3, at 9 a.m. CDT at the Houston Marriott Westchase, 2900 Briarpark Drive, Houston, TX 77042. Shareholders must present an admission ticket or proof of ownership of Phillips 66 stock, as well as valid picture identification, to be admitted.
Those unable to attend in person can access live audio of the meeting by going to the Phillips 66 Investors site, www.phillips66.com/investors, and clicking on “Events & Presentations.” A toll-free conference call number and access code will be listed there. A transcript will be available on Phillips 66’s Investors site at a later date.
Final voting results from the meeting will be reported on Form 8-K and filed with the Securities and Exchange Commission.
About Phillips 66
Phillips 66 is a diversified energy manufacturing and logistics company. With a portfolio of Midstream, Chemicals, Refining, and Marketing and Specialties businesses, the company processes, transports, stores and markets fuels and products globally. Phillips 66 Partners, the company's master limited partnership, is an integral asset in the portfolio. Headquartered in Houston, the company has 14,800 employees committed to safety and operating excellence. Phillips 66 had $52 billion of assets as of Dec. 31, 2016. For more information, visit www.phillips66.com or follow us on Twitter @Phillips66Co.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330006026/en/
Phillips 66
Rosy Zuklic, 832-765-2297 (investors)
[email protected]
or
C.W.
Mallon, 832-765-2297 (investors)
[email protected]
or
Dennis
Nuss, 832-765-1850 (media)
[email protected]
Source: Phillips 66
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius Group prices upsized $5B convertible notes offering
- Longeveron names Nirav Jhaveri as CFO
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share